Evans W E, Pratt C B
Clin Pharmacol Ther. 1978 Jan;23(1):68-72. doi: 10.1002/cpt197823168.
The kinetics of methotrexate were followed in a patient given two 6-hr infusions of 400 mg/kg in the presence and absence of a pleural effusion. Although the decline in serum concentrations during the first 30 hr after the infusion was similar for the two treatment courses, the half-life beginning 30 hr after the infusion was 6.7 hr without the pleural effusion and 14.4 hr with the pleural effusion. Comparison of the intercompartment distribution rate constants indicated slower movement of the drug back into the central compartment from the peripheral compartment when a pleural effusion was present. Pleural fluid methotrexate concentrations were consistently higher than serum concentrations. These data indicate that the increased risk of toxicity following high-dose methotrexate in patients with pleural effusions is due to changes in methotrexate kinetics resulting in delayed excretion.
在一名患者身上,在有和没有胸腔积液的情况下,对其进行了两次6小时、每次400mg/kg的甲氨蝶呤输注,并跟踪其动力学过程。尽管在输注后的前30小时内,两个治疗疗程的血清浓度下降情况相似,但输注30小时后的半衰期在没有胸腔积液时为6.7小时,有胸腔积液时为14.4小时。房室间分布速率常数的比较表明,存在胸腔积液时,药物从外周室回到中央室的移动较慢。胸腔积液中甲氨蝶呤的浓度一直高于血清浓度。这些数据表明,胸腔积液患者大剂量甲氨蝶呤治疗后毒性风险增加是由于甲氨蝶呤动力学变化导致排泄延迟所致。